Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00451763|
Recruitment Status : Completed
First Posted : March 23, 2007
Last Update Posted : July 23, 2008
Idiopathic Macular Telangiectasia is characterized by incompetent and dilated retinal capillaries in the foveolar region of unknown cause for retinal telangiectasia.
In Idiopathic Macular Telangiectasia, proliferative changes occur in the deep retinal capillary network, leading to intraretinal neovascularization that, unlike in age-related macular degeneration, seems to be retinal rather than choroidal in origin. Before the hemorrhagic and fibrotic state, these vessels may lead to exudation and decrease in the visual acuity. Long-term visual prognosis in patients with this complication may be poor and treatment with laser photocoagulation is unproven. Although newly reported treatment, by photodynamic therapy for neovascular membrane associated with Idiopathic Macular Telangiectasia, may show vision and angiographic stability in a few cases, the improvement may be transient. VEGF has been implicated as the major angiogenic stimulus responsible for neovascularization in AMD, ensuing specific anti-VEGF treatment in these cases.
The purpose of the study is to evaluate intravitreal injection of bevacizumab (1.25mg/0.05ml) in the treatment of Idiopathic Macular Telangiectasia.
|Condition or disease||Intervention/treatment||Phase|
|Retina Telangiectasis||Drug: Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||31 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||December 2006|
|Actual Study Completion Date :||December 2007|
- Visual acuity
- Optical coherence tomography
- Fluorescein angiography
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00451763
|From the Retina and Vitreous Service, Department of Ophthalmology. Sao Rafael Hospital, Monte Tabor Foudation|
|Salvador, Bahia, Brazil, 41253-190|
|Study Director:||Walter Y Takahashi, M.D.||University of São Paulo|
|Principal Investigator:||Otacilio O Maia Jr, M.D.||Sao Rafael Hospital, Monte Tabor Foudation|